Adjuvant immunotherapy results ‘encouraging’ in early NSCLCJune 11, 2019Lung CancerImmunotherapyImmuno-oncology
Checkpoint inhibitor rechallenge is possible for select patientsJune 6, 2019Immuno-oncologyImmunotherapyLung Cancer
Low intensity bridging may be best path to CAR T in adult ALLJune 1, 2019Leukemia, Myelodysplasia, TransplantationImmuno-oncologyImmunotherapy
Novel anti-PD-1 antibody can be given subcutaneouslyMay 31, 2019Immuno-oncologyImmunotherapyHead & Neck/Thyroid Cancers
ICYMI: NIH renames, streamlines gene therapy committeeApril 26, 2019Immuno-oncologyImmunotherapyGene Therapy
Monitoring, early intervention key to CAR T safetyApril 24, 2019ImmunotherapyImmuno-oncologyLymphoma & Plasma Cell Disorders
Creating CAR T-cell therapies for T-cell malignanciesApril 16, 2019Lymphoma & Plasma Cell DisordersLeukemia, Myelodysplasia, TransplantationImmunotherapyImmuno-oncologyRare Diseases
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLCMarch 7, 2019Lung CancerImmuno-oncologyImmunotherapy
Barriers to CAR T use in the spotlight at first European meetingFebruary 28, 2019Immuno-oncologyImmunotherapyGene Therapy
CMS proposes coverage of CAR T-cell therapy in trialsFebruary 15, 2019Practice ManagementImmuno-oncologyImmunotherapyGene Therapy
Immunotherapy’s cardiac effects require early monitoring, managementFebruary 5, 2019Immuno-oncologyImmunotherapyPatient & Survivor CareMelanomaLeukemia, Myelodysplasia, Transplantation
Novel bispecific CAR shows promise in B-cell malignanciesJanuary 25, 2019Lymphoma & Plasma Cell DisordersImmuno-oncologyImmunotherapy
Uninterrupted ibrutinib with CAR T could improve CLL outcomesJanuary 25, 2019Leukemia, Myelodysplasia, TransplantationImmunotherapyImmuno-oncology
Armored CAR protects T cells, induces remissionsJanuary 4, 2019Immuno-oncologyLymphoma & Plasma Cell DisordersImmunotherapy
